№ files_lp_4_process_3_133591
File format: docx
Character count: 51437
File size: 283 KB
Technical specification describing the structure, legal context, and electronic data reporting requirements for the Taxable Payments Annual Report submitted to the Australian Taxation Office.
Year:
2016
Date:
April 2016
Version:
2.0.0
Classification:
UNCLASSIFIED
Subject:
Electronic reporting of taxable payments
Document type:
Technical specification
Issuing organisation:
Australian Taxation Office
Country:
Australia
Target audience:
Software developers
Related legislation:
Taxation Administration Act 1953; Taxation Administration Regulations 1976; Privacy Act 1988
Reporting form:
Taxable Payments Annual Report
Industries covered:
Building and construction industry; government entities providing payments for services or grants
Reporting requirement:
Annual reporting of payments to suppliers or entities with an Australian Business Number
Reporting deadline:
28 August after the end of the financial year
Record length specification:
996 characters per data record
Key entities defined:
Sender; Payer; Payee
Identifiers referenced:
Australian Business Number (ABN)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
Louisiana
Topic:
Fringe Benefits Reporting
Document Type:
Memorandum
Author:
Brian Fleming, CPA, State Accounting Systems Director
Target Audience:
All Executive Branch Departments, Agencies, and Organizational Units
Period of Action:
Calendar year 2025
Approval Date:
January 22, 2026
Amendment Date:
February 2, 2026
Year:
2021–2022
Region / city:
Australia
Subject:
Income Tax, Superannuation Benefits, Defence Force Pensions
Document Type:
Legislative Instrument
Issuing Authority:
Australian Government
Author:
Australian Government
Target Audience:
Recipients of certain pensions under the Defence Force Retirement and Death Benefits Act and Military Superannuation and Benefits Act
Period of Application:
2021–2022 financial year
Date of Approval:
Not specified
Date of Amendments:
Not specified
Year:
2025
Region / City:
St. Louis
Subject:
Tax Election
Document Type:
Form
Organization:
St. Louis University
Author:
Not specified
Target Audience:
Employees of St. Louis University
Effective Period:
2025
Approval Date:
Not specified
Modification Date:
Not specified
Context:
Tax election form for employees of St. Louis University to make voluntary advanced tax deductions based on estimated taxable tuition remission for graduate programs in the calendar year 2025.
Year:
2019
Region / City:
Texas
Topic:
Municipal Bonds
Document Type:
Financial Report
Organization / Institution:
Texas A&M University System
Author:
Not specified
Target Audience:
Investors, Financial Institutions
Effective Period:
From 05/15/2019
Approval Date:
01/29/2019
Amendment Date:
Not specified
Year:
1989
Region / city:
Louisiana
Topic:
Taxable Compensation
Document Type:
Policy Memorandum
Authority:
Office of the Governor, Division of Administration
Target Audience:
Government employees and departments in Louisiana
Effective Period:
July 1, 1989 and onwards
Approval Date:
July 1989
Amendment Dates:
April 1994, August 1999
Year:
2023
Institution:
Saint Louis University
Department:
HR/Benefits Office
Location:
St. Louis
Document Type:
Employee tax election form
Subject:
Tax withholding on taxable tuition remission benefits
Applicable Programs:
MBA; MIB; Social Service; Allied Health; Graduate; Law; Education & Public Service; Graduate School for Professional Studies
Tax Threshold Reference:
Tuition remission value exceeding $5,250 per calendar year
Tax Components:
FICA-OASDI 6.2%; FICA-Medicare 1.45%; Federal withholding 22%; Missouri withholding 4.95%; St. Louis City withholding 1%
Total Withholding Rate:
35.6% of estimated taxable tuition benefit
Additional Condition:
Additional 0.9% Medicare withholding for wages exceeding $200,000
Reference Tuition Rates:
FY23 tuition rates
Submission Method:
Scan and email or submit to HR/Benefits Office, Wool Center
Contact Person:
Monjour Davis
Year:
2017–2025
Region / City:
United Arab Emirates
Type of Document:
Tax Declaration Letter
Organization / Authority:
Federal Tax Authority
Subject:
Business Sales and Tax Reporting
Business Name:
[Redacted/Not specified in document]
Tax Registration Threshold:
Mandatory AED 375,000 / Voluntary AED 187,500
Start of Taxable Supplies:
[Date specified as "Type Month and Year Here"]
Supporting Documents:
Invoices, LPOs, Contracts, Title Deeds, Tenancy Contracts
Currency:
AED
Frequency of Reporting:
Monthly and Yearly
KHG Housing Strategy and Enabling Subgroup Meeting Notes, 13th January 2026, 2:00 – 3:30pm, on Teams
Year:
2026
Region / City:
Kent & Medway
Topic:
Housing Strategy and Affordable Housing
Document Type:
Meeting Notes
Organization:
Kent Housing Group (KHG)
Author:
N/A
Target Audience:
KHG members, local authorities, housing professionals
Period of Effectiveness:
N/A
Approval Date:
13th January 2026
Date of Changes:
N/A
Year:
2024
Region / City:
Australia
Topic:
Medicinal Product Registration
Document Type:
Submission Report
Agency:
Therapeutic Goods Administration (TGA)
Author:
GlaxoSmithKline Australia
Target Audience:
Medical Practitioners
Treatment Phase:
Initial Treatment
Indication:
Myelofibrosis, including primary, post-polycythaemia vera, and post-essential thrombocythaemia myelofibrosis
Approval Status:
Pending
Date of Submission:
May 2024
Date of Approval:
Not yet approved
Background:
Momelotinib is currently approved in the UK, US, Japan, and the EU.
Description:
Clinical submission for listing momelotinib under the Australian PBS for the treatment of myelofibrosis in patients with moderate to severe anaemia.
Year:
2019
Region / City:
San Clemente, CA
Subject:
Criminal Law
Document Type:
Course Outline
Institution:
Grossmont College
Author:
Richard Michelson, James Zuffoletto, M. R. Lippman
Target Audience:
Students of Criminal Justice
Period of Application:
Fall Semester 2019
Approval Date:
December 13, 2019
Location:
Academic Senate Conference Room (AS 125)
Year:
2019
Region / City:
Long Beach, California
Subject:
Executive Committee Meeting Minutes
Document Type:
Meeting Minutes
Organization / Institution:
California State University, Long Beach (CSULB)
Author:
J. Pandya, N. Hultgren, M. Aliasgari, N. Meyer-Adams, C. Cummings, P. Hung, D. Stewart, N. Schürer, K. Janousek, E. Klink, P. Soni, J. Phillips, D. Hamm, K. Bonetati, J. Hamilton, S. Apel, B. Jersky, J. Cormack, A. Kinsey
Target Audience:
Faculty, Academic Senate, Executive Committee members
Period of Validity:
Not specified
Approval Date:
August 27, 2019
Amendment Date:
Not specified
Note:
Year
Year:
2026
Region / City:
Northport, New York
Topic:
Roof Replacement, Architectural Design
Document Type:
Design Submission Instructions
Institution:
Department of Veterans Affairs
Author:
Department of Veterans Affairs
Target Audience:
Architects/Engineers involved in VA projects
Effective Period:
Ongoing
Approval Date:
Not specified
Date of Amendments:
Not specified
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.
Year:
2013
Region / City:
Hillston
Topic:
Annual General Meeting, Water Policy, Agriculture, Irrigation
Document Type:
Meeting Minutes
Organization:
Lachlan Valley Water Inc
Author:
Dennis Moxey (Chairman)
Target Audience:
Members of Lachlan Valley Water Inc, Stakeholders in Water and Irrigation Policy
Period of Action:
12 September 2013
Approval Date:
12 September 2013
Date of Changes:
Not specified
Note:
Year
Document Type:
Policy Template
Governing Body:
State Water Board
Intended Audience:
Public Water System Operators
Service Connections Covered:
Single-family, Multifamily, Commercial, Industrial, Agricultural, Landscape
Legal Authority:
Operating rules / Ordinance / Board resolution / Bylaw
Certification Requirements:
ANSI/DDW recognized cross-connection control specialist
Inspection Frequency:
Initial and ongoing hazard assessments
Backflow Prevention Requirements:
Inventory, testing, maintenance, corrective actions
Incident Response:
Reporting and notification procedures
Public Outreach:
Education methods for customers, staff, and community
Year:
2024
Region / City:
Raleigh
Theme:
Office Space Leasing
Document Type:
Proposal
Agency / Organization:
North Carolina Department of Revenue
Author:
Sam Tucker
Target Audience:
Proposers
Effective Date:
October 17, 2024
Deadline for Proposal Submission:
October 23, 2024 at 4:00 PM ET
Electronic Submission Portal:
NC eProcurement Electronic Vendor Portal
Proposal Number:
92-966-FINAL
Year:
2022
Region / City:
Australia
Theme:
Oncology, Medical Treatment
Document Type:
Pharmaceutical Submission
Organization / Institution:
Bristol-Myers Squibb Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical professionals, Oncologists
Period of validity:
Ongoing
Approval Date:
4 July 2018
Date of Changes:
Not specified
Note:
Contextual Description
Year:
2021
Region / City:
Australia
Topic:
Atopic dermatitis treatment, medication submission
Document Type:
Submission report
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Sanofi-Aventis
Target Audience:
Medical professionals, regulatory authorities
Action Period:
Ongoing treatment evaluation
Approval Date:
17 August 2021
Modification Date:
Not specified
Background:
Dupilumab registration history
Clinical Claim:
Dupilumab has superior efficacy compared to standard care for children with severe atopic dermatitis
Episodicity:
Chronic
Severity:
Severe
Condition:
Atopic dermatitis
PBS Indication:
Chronic severe atopic dermatitis
Prescriber Type:
Medical practitioners, dermatologists, clinical immunologists
Treatment Phase:
Initial, continuing
Population Criteria:
Children aged 6 to 11 years, specific weight ranges
Comparator:
Placebo
Outcomes:
EASI-75, IGA 0 or 1 at Week 16, improvement in itch score
Dosing:
Tiered by body weight
Cost:
$1,754.28–$3,380.91
Price:
Published price for maximum quantity
Form:
Pre-filled syringe
Medical Information:
Dupilumab 300 mg/2 mL, 200 mg/1.14 mL
Note:
Comparator
Standard of care (Placebo)
Source:
PBAC submission
Year:
2019
Region / City:
Vancouver, WA
Theme:
Diversity, Equity, Legislative Action, Community Outreach
Document Type:
Meeting Minutes
Organization:
CAPAA
Author:
Lisa Dickinson, Nam Nguyen, Carrie Huie-Pascua, Lori Wada, Tam Dinh, Mohan Gurung, Ekkarath Sisavatdy, Sam Cho, Sina Sam, Helen Christensen, Lydia Faitalia
Target Audience:
CAPAA Members, Community Leaders, Public Health Advocates, Immigrant Communities
Period of Activity:
September 21, 2019
Date of Approval:
September 21, 2019
Date of Changes:
N/A